Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNC1 | P63316 | 6/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403253 | 1.00 | TNNC1 (0.39) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL19291174 | 0.79 | S1PR1 (0.54) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5409598 | 0.79 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL5407214 | 0.78 | S1PR1 (0.58) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5407205 | 0.78 | S1PR1 (0.58) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL14593239 | 0.77 | S1PR1 (0.65) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL13614227 | 0.75 | CYP1A2 (0.47) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL22113055 | 0.75 | ALDH1A1 (0.42) | TNNC1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5033468 | 0.75 | ALDH1A1 (0.46) | TNNC1 | |
| SCHEMBL7518860 | 0.75 | CA2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511473-B1 | BIS-AROMATIC ALKANOLS | NOVARTIS AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | IRM LLC (BM) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | CD4, HLA-DRB1, MALT1 | TNNC1 2029/4885S1PR1 1541/4885S1PR3 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.